Skip to main content

Evotec initiates ‘Campus Curie’ in Toulouse

Drug discovery firm Evotec, which also owns the CDMO Aptuit, has acquired the ‘Biopark by Sanofi’ (BBS) operation in Toulouse, France, and will rename it ‘Campus Curie’. The 19 employees are all transferring. Financial terms were not disclosed.

The company said that this acquisition will allow it “to significantly expand its existing capacities at the site over the near to mid-term while retaining maximum flexibility to build up long-term capacity as needed”.

Carlyle Group invests in Piramal

Via CA Clover Intermediate II Investments, private equity firm the Carlyle Group is to invest about $940 million in fresh equity capital for a 20% stake in Piramal Pharma, the healthcare subsidiary of Indian conglomerate Piramal Enterprises (PEL). This values the business at $2,775 million with an upside component of up to $360 million depending on the company’s performance this financial year.

Cambrex invests in Sweden

Small molecule CDMO Cambrex is to spend $3.6 million to increase flexible drug substance manufacturing capacity by 6 m3 (25%) at Karlskoga, Sweden, in response to growing demand for commercial-scale API manufacturing. Engineering work has already commenced and should be completed by November.

Feature article – Covid-19 & a CDMO: A case study

Nicolas Biz, CDMO chief project officer, shows how Seqens rapidly developed production of a key material in the fight against Covid-19

Pending the availability of a vaccine, which will necessarily take time, the race against the clock is under way to identify and develop an anti-viral molecule effective against Covid-19. Research is taking place at an unprecedented speed, with more than 1,900 clinical trials listed worldwide since the start of the pandemic. Of these, 912 are in the process of patient testing.

Feature article - A CDMO’s insight into the M&A landscape

Mark Quick, EVP of  corporate development at Recipharm, discusses the M&A trend within the CDMO industry

M&A activity within the pharmaceutical industry remains at a high. According to Ernst & Young (EY), M&A strategies have increased by around 12% year-on-year since 2012.1 CDMOs are some of the major players in these high-value deals, seeing it as a valuable strategy that enables to capitalise on another company’s strengths and thus better position their organisations to meet market demands and realise a more competitive edge.

CDMOs partnering in Covid-19 initiatives

Several of the world’s major pharmaceutical CDMOS have recently made announcements relating to their participation in projects to develop treatment for the Covid-19 virus. Many involve chloroquines, in anticipation of their large-scale use.

Bachem in Molecular Hiving deal

Bachem, the world’s largest producer of pharmaceutical peptides and ologonucleotides, has signed an exclusive licensing agreement with Japanese firm Jitsubo related to the latter’s liquid-phase peptide technology. Molecular Hiving. Financial terms were not disclosed. The two firms have already worked together on APIs and cosmetic peptides.

Subscribe to Pharmaceuticals

 

 

 

AMRI banner advert